Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover

What Was Tested

Researchers studied Calcitonin in the context of osteoporosis and bone density in this randomized controlled trial publication.

To investigate acute effects of calcitonin treatment on bone resorption markers in elderly women, the researchers conducted a randomized trial in women >65 years of age with high bone turnover assessed as urinary N-telopeptide of type-I collagen (NTx) levels 1 SD higher than mean premenopausal levels, which was irrespective of bone density.

Why It Was Studied

Salmon calcitonin is a potent inhibitor of osteoclastic activity.

Blood and urine samples were collected at 0, 2, 4, and 6 months and analyzed for urinary NTx and serum C-telopeptide of type-1 collagen (CTx).

Who Took Part

According to the abstract, 98 women were involved.

The age groups tagged for this paper are older adults, women only.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Calcitonin and who got the comparison, which limits bias.

The timeline in the abstract includes 6 months.

What Was Measured

The spine and total hip BMD, serum PTH levels and urinary calcium/creatinine ratios were similar in both groups.

The subject headings attached to it are Biomarkers, Bone Density, Bone Resorption, Calcitonin, Collagen and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized study of Calcitonin in 98 women in people with osteoporosis and bone density over 6 months.

The publication is from 2004 (Calcified tissue international), a journal based in United States.

More context: the Calcitonin compound page, Osteoporosis and bone density research.